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ABSTRACT
The transcription factor SOX9 plays a critical role
in chondrogenesis as well as in sex determination.
Previous work has suggested that SOX9 functions
as a DNA-dependent dimer when it activates
genes involved in chondrogenesis, but functions
as a monomer to activate genes involved in sex
determination. We present evidence herein for
a third binding configuration through which SOX9
can activate transcription. We have identified four
separate SOX consensus sequences in a COL9A1
collagen gene enhancer. The sites are arranged
as two pairs, and each pair is similar to previously
discovered dimeric SOX9 binding sites. Increasing
the spacing between the pairs of sites eliminated
enhancer activity in chondrocytic cells, as did the
mutation of any one of the four sites. The COL9A1
enhancer is ordinarily inactive in 10T1/2 cells,
but cotransfection with a SOX9 expression plasmid
was sufficient to activate the enhancer, and
mutation of any one of the four sites reduced
responsiveness to SOX9 overexpression. These
results suggest a novel mechanism for transcrip-
tional activation by SOX9, in which two SOX9 dimers
that are bound at the two pairs of sites are required
to interact with one another, either directly or
indirectly, in order to produce a functional
transcriptional activation complex.
INTRODUCTION
The transcription factor SOX9 is critical for normal
embryonic development. SOX9 is a member of the high-
mobility group (HMG) superfamily and contains an
HMG DNA binding domain, as well as a transactivation
domain and a DNA-dependent dimerization domain (1).
It is related to the testes determining factor gene SRY,
and the SOX family of proteins was named for this
relationship; SOX stands for SRY-type HMG box (2).
SOX9 plays a critical role in chondrogenesis, as
demonstrated by knockout mouse experiments in which
all cells bearing a homozygous targeted mutation in the
SOX9 gene were excluded from the chondrocyte diﬀer-
entiation pathway (3). Evidence from the human disease
campomelic dysplasia, which results from mutations in
the SOX9 gene, indicates that SOX9 functions in sex
determination as well as in chondrogenesis. Campomelic
dysplasia is always characterized by severe cartilage
abnormalities, but about two-thirds of chromosomally
male patients also exhibit XY sex reversal (4–6).
A number of enhancer elements from genes involved
in both chondrogenesis and sex determination have been
shown to be directly activated by SOX9. We have
previously identiﬁed three separate chondrocyte-speciﬁc
enhancer elements in the type XI collagen gene Col11a2
(7,8). Each enhancer binds dimeric SOX9at paired
binding sites arranged in opposite orientation to each
other and separated by three or four base pairs (bp).
Mutation of either site in a pair inactivated the enhancer,
as did changing the spacing between paired sites,
indicating that the dimeric SOX9 interaction is essential
for enhancer activity. We have also shown that the
type XXVII collagen gene COL27A1 contains at least two
similar enhancer elements that bind SOX9at paired sites,
and mutation of either site in a pair also inactivated those
enhancers (9). Furthermore, enhancers from the cartilage-
speciﬁc genes Col2a1, Col9a2, and the cartilage-derived
retinoic-acid-sensitive protein (CD-RAP) all contain
paired binding sites for SOX9 (10–14).
In contrast, enhancers from the anti-Mullerian hor-
mone (AMH) gene and the Steroidogenic Factor 1 (SF1)
gene, which both play a critical role in sex determination
and are both activated by SOX9, only contain one SOX9
binding site each (12,15). This evidence led to the
hypothesis put forth by Bernard et al. in 2003 that
dimerization of SOX9 is required for the activation of
genes involved in chondrogenesis but not for those
involved in sex determination (12). This hypothesis is
further supported by a human case of campomelic
dysplasia in which a missense mutation (A76E) in the
dimerization domain of SOX9 resulted in chondrodys-
plasia but not sex reversal (12,15). In enhancer/reporter
assays, the A76E SOX9 dimerization mutant was found
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enhancers normally, but did not activate either the
Col11a2 or Col9a2 cartilage enhancers (12,15).
Prior to the publication of the dimerization-for-
chondrogenesis hypothesis, work was published identify-
ing an enhancer region in the type IX collagen gene
COL9A1 in which only one SOX9 binding site was
pinpointed as being essential for enhancer activity in
chondrocytic cells (16). We suspected that this enhancer
might also be subject to regulation by dimerized SOX9,
and upon examining the sequence we identiﬁed a second
potential SOX9 binding site 4bp upstream from the ﬁrst
site and oriented appropriately for the binding of dimeric
SOX9. Surprisingly, however, the candidate enhancer
sequence we initially constructed, which contained the
paired sites, had no activity in enhancer/reporter assays.
Instead, enhancer activity required the inclusion of 54
additional bp upstream. This upstream sequence included
two more previously unidentiﬁed SOX consensus
sequences. All four sites were found to bind SOX9, and
each was essential for the activity of the enhancer element;
mutation of any one of the four sites completely abolished
enhancer activity in chondrocytic cells.
The results presented herein suggest a novel
mechanism by which gene expression can be regulated
by the transcription factor SOX9. It appears that, in the
COL9A1 enhancer, two interdependent SOX9 dimers are
required for transcriptional activation. Mutations that
inactivated either dimer by preventing binding of one of
the SOX9 molecules left the other dimeric binding site
incapable of transcriptional activation. Likewise, insertion
mutations that increased the spacing between the two
dimerization sites eliminated enhancer activity, demon-
strating the necessity of a dimer–dimer interaction for
transcriptional activation.
EXPERIMENTAL PROCEDURES
Plasmid construction
COL9A1 D1/D2 4x enhancer/reporter plasmid. Comple-
mentary oligonucleotides were designed for a 50-bp
portion of the COL9A1 D enhancer region described by
Zhang et al. (16), containing either wild-type paired SOX9
binding sites (D1/D2) or substitution mutations in either
the upstream or downstream site within each pair to
generate D1 /D2 and D1/D2 , respectively (Figure 1A).
Mutant sites contained a total of four mismatches with the
consensus SOX binding sequence,
A/T
A/TCAA
A/TG.
Complementary single-strand DNA oligonucleotides
were puriﬁed by denaturing polyacrylamide gel electro-
phoresis, annealed and cloned into the BamHI-BglII site
of the p89Col2a1Bs plasmid. The enhancer elements were
multimerized to four tandem copies as previously
described and transferred with the minimal promoter to
the luciferase reporter plasmid p95Luc, resulting in four
repeats of the enhancer upstream of the Col2a1 minimal
promoter and luciferase reporter gene (7). Constructs were
veriﬁed by sequencing in the BYU DNA Sequencing
Center (BYU DNASC).
COL9A1 M1/M2/D1/D2 1x enhancer/reporter
plasmid. To create the COL9A1 M1/M2/D1/D2 enhancer
plasmid, PCR was used to amplify the 96-bp COL9A1
D enhancer region described by Zhang et al. (16)
(Forward TTAAGGATCCAGTG GGCACATTTTTAC,
Reverse GGCGAGATCTATC TGCTATAGGAGTAC)
(Figure 1C). DNA template was extracted from human
white blood cells using the DNeasy Tissue Kit (Qiagen).
The ampliﬁed enhancer region was cloned into the
BamHI-BglII site of the p89Col2a1Bs plasmid. The
enhancer and minimal promoter were then transferred
to the luciferase reporter plasmid p95Luc, and correct
construction was veriﬁed by DNA sequencing in the
BYU DNASC.
Mutations were made to each of the four putative SOX9
binding sites located within the COL9A1 M1/M2/D1/D2
enhancer using QuikChange II Site-Directed Mutagenesis
(Stratagene) resulting in the mutants M1 /M2/D1/D2,
M1/M2 /D1/D2, M1/M2/D1 /D2 and M1/M2/D1/D2 
(Figure 1D) where each mutated SOX9 binding site
contained a total of four mismatches to the SOX binding
consensus sequence. To construct mutants M1/M2/A /
D1/D2 and M1/M2/B /D1/D2, 4bp (A, CTAT; B,
GTCA) were inserted between the two pairs of SOX9
binding sites using QuikChange II Site-Directed
Mutagenesis (Stratagene).
SOX9 D66-75 expression plasmid. Mutations were intro-
duced into the wild-type SOX9-pcDNA-50-UT expression
plasmid using QuikChange II Site-Directed Mutagenesis
(Stratagene). Mutant SOX9 66–75 is a de novo human
mutation described by Sock et al. (15), which results
in the loss of amino acids 66–75 in the conserved
DNA-dependent dimerization domain.
Tissue cultureand transfections
Rat chondrosarcoma (RCS) cells and 10T1/2 cells were
agift fromDr. Benoit de Crombruggheof theUniversity of
Texas M.D. Anderson Cancer Center. Cells were cultured
at378Cwith5%CO2insupplementedDulbecco’smodiﬁed
Eagle medium (D-MEM) (Gibco). Supplemented medium
contained 50U/ml penicillin (Cellgro), 50mg/ml strepto-
mycin(Cellgro),2mM L-glutamine(Cellgro) and10%fetal
bovine serum (HyClone). RCS and 10T1/2 cells were
transiently transfected using Lipofectamine Reagent with
PlusReagent (Invitrogen), according to the manufacturer’s
instructions. The plasmid pSV-b-galactosidase (Promega)
was included in every reaction as an internal control
for transfection eﬃciency, and a total of 2.0mg of DNA for
RCS transfections and 1.4mg of DNA for 10T1/2 transfec-
tions were used in each 10-cm
2 well.
Following transfection, cellular extracts were prepared
and enzyme activity assays performed. Luciferase activity
was measured using the Luciferase Assay system
(Promega), and b-galactosidase activity was measured
using the Galacto-Light Plus system (Tropix), both
according to manufacturer’s instructions. Results were
measured in a TD 20/20 luminometer (Turner Designs)
and are presented as luciferase units per b-galactosidase
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Electrophoretic mobility shift assay(EMSA)
EMSAs were performed using wild-type and mutant
versions of the COL9A1 D1/D2 element, the M1/M2
element and the M1/M2/D1/D2 element as DNA probes
(see Figure 1 for sequences), which were
32P radiolabeled
by end-ﬁlling with Klenow fragment. SOX9 was
synthesized by in vitro transcription/translation of
SOX9-pcDNA-50-UT expression plasmid using the TNT
Coupled Wheat Germ Extract System (Promega).
DNA-protein binding reactions were performed with
radiolabeled probes and SOX9, either wild type or the
66–75 mutant, with or without anti-SOX9 antibody.
Reactions were carried out at room temperature for
45min in a DNA-binding buﬀer containing 20mM Hepes
(pH 7.9), 10% glycerol, 50mM KCl, 0.05% Nonidet
NP-40, 0.5mM EDTA, 0.5mM DTT, and 1mM PMSF.
Poly(dG-dC)Epoly(dG-dC) (0.5–2mg) was added as
a nonspeciﬁc competitor. When anti-SOX9 antibody was
included, it was pre-incubated with SOX9 for 20–30min
before the addition of radiolabeled probes. Binding
reactions were separated by electrophoresis for 3–4h
at 150V.
RESULTS
After the putative SOX9 binding site D1 was identiﬁed
adjacent to the known site, D2, EMSAs were performed to
Figure 1. Sequences from the COL9A1 enhancer region. SOX9 binding consensus sequences are marked with grey background, and arrows indicate
site orientation. Mismatches with the SOX9 consensus sequence are underlined, and introduced mutations are bold. (A) The D1/D2 element contains
the SOX9 binding site (D2) that was previously shown by Zhang et al. (16) to be critical for COL9A1 enhancer activity. Mutations were introduced
into the D1 site (D1 /D2) or the D2 site (D1/D2 ) to produce a total of four mismatches with the SOX binding consensus sequence
A/T
A/TCAA
A/TG.
(B) The M1/M2 element includes the newly identiﬁed binding sites upstream of the D1/D2 element. M1 /M2 and M1/M2  mutants contain four
mismatches with the SOX binding consensus sequence. (C) Sequence of the full-length M1/M2/D1/D2 enhancer. Brackets indicate the boundaries of
the probes used for EMSA. (D) Mutants of the M1/M2/D1/D2 enhancer.
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included wild-type D1/D2, as well as mutants D1 /D2 and
D1/D2  (Figure 1A). Mutant binding sites contained four
mismatches with the SOX binding consensus sequence
A/T
A/TCAA
A/TG. The EMSAs showed that SOX9 bound
as a dimer and a monomer to the wild-type COL9A1
D1/D2 element (Figure 2, lane 1). Inclusions of anti-SOX9
antibody supershifted both complexes, conﬁrming that
they both contain SOX9 (Figure 2, lane 2). Mutation of
the D1 site (D1 /D2) allowed for monomeric binding
at the D2 site, but prevented dimeric SOX9 binding
(Figure 2, lanes 3 and 4). Mutation of the D2 site
(D1/D2 ), however, prevented both dimeric and mono-
meric binding, even though the D1 site was still intact
(Figure 2, lanes 5 and 6). This result suggested that
binding of SOX9at the D1/D2 pair of sites occurs
cooperatively and sequentially, with binding at the D2
site required before binding at the D1 site can occur.
The D1 site is not capable of binding a SOX9 monomer.
To determine whether the binding of SOX9 to the
wild-type and mutant COL9A1 D1/D2 elements in vitro
correlated with transcriptional activity in vivo, transient
transfections were performed using enhancer/reporter
plasmids in RCS cells where SOX9 is endogenously
expressed. To our surprise, neither the wild-type nor
mutant D1/D2 elements displayed any enhancer activity
in RCS cells (Figure 3).
Although they did not contain the full-length enhancer
previously identiﬁed by Zhang et al. (16), these elements
did contain the same SOX9 binding site, D2, which
had been identiﬁed as the critical site for activation.
We hypothesized, therefore, that another critical sequence
must exist in the upstream region contained in Zhang’s
enhancer but omitted from our D1/D2 element. To test
this hypothesis, the same enhancer region as described
by Zhang et al. (Figure 1C) was used to construct
a single-copy enhancer/reporter plasmid, which was
tested in transient transfections in RCS cells. The full-
length 96-bp element (M1/M2/D1/D2) displayed signiﬁ-
cant enhancer activity (P50.0001), indicating that the
upstream region does indeed contain additional critical
sequences (Figure 3).
The upstream region was examined for possible
transcription factor binding sites, and two new putative
SOX9 binding sites arranged in opposite orientation to
each other and separated by 4bp were discovered. The site
designated M1 was a 2-bp mismatch with the SOX
consensus sequence, and the M2 site was a 1-bp mismatch
(Figure 1B). EMSAs were performed using probes
containing only the M1 and M2 sites to determine
whether SOX9 bound in vitro to these newly identiﬁed
sites. Probes used included wild-type M1/M2, as well as
Figure 2. Dimeric and monomeric SOX9 bind to the COL9A1 D1/D2
and M1/M2 elements. EMSA was performed using SOX9 made in vitro
and wild-type or mutant probes as indicated. Anti-SOX9 antibody
supershifted both monomeric and dimeric complexes of SOX9 with the
wild-type D1/D2 probe (compare lanes 1 and 2). Mutation of the D1
site (D1 /D2) allowed only monomeric SOX9 binding (lanes 3 and 4).
Mutation of the D2 site (D1/D2 ) completely prevented all SOX9
binding (lanes 5 and 6). Anti-SOX9 antibody also supershifted both
monomeric and dimeric complexes of SOX9 with the wild-type M1/M2
probe (compare lanes 7 and 8). Mutation of the M1 site (M1 /M2)
prevented dimeric SOX9 binding (lanes 9 and 10). Mutation of the
M2 site (M1/M2 ) completely prevented all SOX9 binding (lanes 11
and 12). The right and left panels contain lanes from the same EMSA
experiment, but the panel on the right was exposed longer because
SOX9 binding to the M1/M2 element was very weak compared to
D1/D2 binding.   denotes a nonspeciﬁc band.
Figure 3. The D1/D2 element has no enhancer activity. Transient
transfections were performed in RCS cells using reporter plasmids
containing four tandem copies of the short D1/D2 element or a single
copy of the longer M1/M2/D1/D2 enhancer. Neither wild-type D1/D2
nor corresponding mutants activated gene expression. The longer
M1/M2/D1/D2 enhancer, however, was transcriptionally active in RCS
cells, as previously reported (16). Graph includes data from three
independent experiments, each performed in triplicate, and data was
normalized to the activity of the D1/D2 element.
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of anti-SOX9 antibody to the wild-type binding reaction
resulted in an antibody shift indicating that SOX9 binding
did occur at this pair of sites (Figure 2, lanes 7 and 8).
Binding was very weak, however, compared to the D1/D2
element, and visualization of the complex required longer
exposure of the X-ray ﬁlm. When the M1 site was
mutated, SOX9 still bound weakly to the M2 site and
was supershifted by anti-SOX9 antibodies (Figure 2, lanes
9 and 10). But when the M2 site was mutated, no SOX9
binding occurred (Figure 2, lanes 11 and 12), suggesting
that, as with the D1/D2 pair of sites, SOX9 binding occurs
in a cooperative sequential manner with monomeric
binding at the M2 site required before dimerization
can occur. The M1 site is not capable of binding
monomeric SOX9.
To determine whether these newly identiﬁed SOX9
binding sites were important for the transcriptional
activity of the full-length M1/M2/D1/D2 enhancer,
substitution mutations were introduced within each site
and the mutant enhancers were tested in enhancer/
reporter assays. The D1 and D2 sites were also mutated
in the context of this longer enhancer (Figure 1D).
Surprisingly, introducing a mutation into any one of the
four putative SOX9 binding sites within the M1/M2/D1/
D2 enhancer resulted in the complete elimination of
enhancer activity in chondrocytic RCS cells (Figure 4).
To verify that the activity of the M1/M2/D1/D2
enhancer was the result of SOX9 transactivation,
enhancer/reporter assays were performed in 10T1/2 cells,
which do not express SOX9. The wild-type M1/M2/D1/
D2 enhancer showed a nonsigniﬁcant level of transcrip-
tional activity (P¼0.053) in the absence of SOX9, and
none of the four mutants was signiﬁcantly diﬀerent from
the wild-type level of activity in the absence of SOX9
(P40.165) (Figure 5, white bars). Cotransfection with the
SOX9 expression plasmid, however, strongly activated
the wild-type M1/M2/D1/D2 enhancer (P50.0001).
Individual mutation of the M1, M2 or D1 sites reduced
activation to between 30 and 50% of wild type, and
mutation of the D2 site eliminated activation by SOX9
(Figure 5, grey bars), demonstrating that each of the four
sites participates in transactivation by SOX9.
To examine the importance of SOX9 dimerization
for activation of the full-length M1/M2/D1/D2 enhancer,
the i66–75 mutant of SOX9 was used in EMSAs and
enhancer/reporter assays. As previously shown, SOX9
that is lacking amino acids 66–75 within the dimerization
domain is incapable of DNA-dependent dimerization and
is unable to activate enhancers that require dimeric SOX9
binding (15). Elements M1/M2, D1/D2 and M1/M2/D1/
D2 were used as probes in EMSA with i66–75 SOX9
(Figure 6). With each probe, the dimeric SOX9 band was
lost and the intensity of the monomeric band increased
when i66–75 was substituted for SOX9 in the binding
reaction (Figure 6, lanes 4, 9 and 14).
To see if transcriptional activation could occur in the
absence of SOX9 dimerization, enhancer/reporter assays
were performed using i66–75 mutant SOX9 overexpres-
sion in 10T1/2 cells. The M1/M2/D1/D2 enhancer and
Figure 4. Mutation of any one of the four SOX sites in the M1/M2/
D1/D2 element abolishes enhancer activity in RCS cells. Transient
transfections were performed in RCS cells using reporter plasmids
containing the wild-type enhancer (M1/M2/D1/D2) or mutant
enhancers (M1 /M2/D1/D2, M1/M2 /D1/D2, M1/M2/D1 /D2 and
M1/M2/D1/D2 ). Results were normalized to the activity of the
wild-type enhancer. Each panel contains data from three independent
experiments, performed in triplicate.
Figure 5. SOX9 overexpression activates the M1/M2/D1/D2 enhancer
in 10T1/2 cells. Transient transfections were performed in 10T1/2 cells
using reporter plasmids containing the wild-type enhancer (M1/M2/
D1/D2) or mutant enhancers (M1 /M2/D1/D2, M1/M2 /D1/D2,
M1/M2/D1 /D2 and M1/M2/D1/D2 ). Cells were cotransfected with
the SOX9 or the i66–75 SOX9 mutant expression plasmid. Results
were normalized to the activity of the wild-type enhancer cotransfected
with SOX9.
1182 Nucleic Acids Research, 2007, Vol. 35, No. 4each of the four mutant enhancer elements were tested.
The i66–75 mutant SOX9 produced approximately half
as much activation of the M1/M2/D1/D2 enhancer as
wild-type SOX9, indicating that dimerization is required
for full activation. Interestingly, however, when tested
with enhancers containing mutations in the M1, M2, D1
or D2 sites individually, the i66–75 SOX9 mutant
protein was not less active than wild-type SOX9
(Figure 5, black bars).
To determine whether the spacing between the two pairs
of SOX9 binding sites was a signiﬁcant factor in enhancer
activation, RCS cells were transfected with mutant
enhancer/reporter plasmids containing two diﬀerent 4-bp
insertion mutations between the two paired SOX9 binding
sites (M1/M2/A /D1/D2 and M1/M2/B /D1/D2).
Two diﬀerent insertions were used in order to verify that
the speciﬁc sequence of the inserted DNA had no inherent
activity. These insertions increased the space between
the two dimeric binding sites from 14 to 18bp and thus
oﬀset the two pairs of binding sites by nearly half a turn of
the DNA helix. The presence of either insert resulted
in complete inactivation of the enhancer, suggesting that
the SOX9 dimers bound at the two pairs of sites must
interact, either directly or indirectly, to form a complex
that results in transcriptional activation (Figure 7).
Although our results had shown that cotransfection
with SOX9 was suﬃcient to activate the M1/M2/D1/D2
enhancer in 10T1/2 cells, and mutation of any one of the
four SOX consensus sites reduced responsiveness to
SOX9, we wondered whether other SOX family proteins
besides SOX9 might bind to some of the sites and
cooperate with SOX9 to regulate transcription. The
proteins L-SOX5 and SOX6 have been shown to cooperate
with SOX9 to activate the type II collagen gene, Col2a1,
through binding to a chondrocyte-speciﬁc enhancer with
multiple SOX consensus sequences (17). The loss of both
L-Sox5 and Sox6 results in severe cartilage abnormalities
in a dual knock-out mouse, so we wondered if L-Sox5 and
Sox6 might also help activate the COL9A1 M1/M2/D1/
D2 enhancer in cartilage cells (18). Plasmids expressing
L-Sox5 and Sox6 were included in addition to the SOX9
expression plasmid in M1/M2/D1/D2 enhancer/reporter
assays in 10T1/2 cells, to see if either protein could
regulate transcriptional activity independently or in
cooperation with SOX9. Neither L-Sox5 nor Sox6 had
any eﬀect on the level of activation produced by SOX9
(data not shown), suggesting that SOX9 binds to all four
SOX consensus sequences in the COL9A1 M1/M2/D1/D2
enhancer and that L-Sox5 and Sox6 do not play a role in
activating this enhancer.
EMSAs were performed to determine whether the
same mutations that eliminated M1/M2/D1/D2 enhancer
activity in enhancer/reporter assays also prevented
SOX9 binding in vitro. Inclusion of anti-SOX9 antibodies
demonstrated that although binding was reduced,
Figure 6. The i66–75 SOX9 mutant cannot dimerize at M1/M2/D1/
D2 SOX9 binding sites. EMSA was performed using the M1/M2, D1/
D2 or M1/M2/D1/D2 elements as probes and either SOX9 or i66–75
mutant SOX9 as indicated. The i66–75 SOX9 mutant bound to these
probes only as a monomer. Lanes 1, 6 and 11 contain the in vitro
protein synthesis reaction blank control. The three panels all contain
lanes from the same EMSA experiment, but the panel on the left was
exposed longer because SOX9 binding to the M1/M2 probe was very
weak compared to the other two probes.  denotes a nonspeciﬁc band.
Figure 7. Insertion of 4bp between the two SOX9 binding site pairs
eliminates enhancer activity. Transient transfections were performed in
RCS cells using reporter plasmids containing the wild-type enhancer
(M1/M2/D1/D2) or enhancers containing one of two diﬀerent 4-bp
insertions between the two SOX9 binding site pairs (M1/M2/A /D1/D2
and M1/M2/B /D1/D2). Both insertions eliminated enhancer activity.
Graph includes data from three independent experiments, each
performed in triplicate, and data was normalized to the activity of
the wild-type enhancer.
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D1 sites were mutated (Figure 8). Mutation of the D2 site,
however, eliminated SOX9 binding, suggesting that SOX9
must bind ﬁrst to the D2 site before the rest of the SOX9
complex can assemble. Taken together with the enhancer/
reporter assay results presented in Figure 4, these results
indicate that even though some SOX9 complex assembly
can occur when the M1, M2 or D1 sites are mutated,
the partially assembled SOX9 complexes are completely
inactive for the purposes of transcriptional activation
in chondrocytic cells.
DISCUSSION
This work has resulted in the discovery of a new type
of enhancer element through which the chondrogenic
transcription factor SOX9 can activate transcription.
Previously discovered enhancer elements from the
Col11a2, COL27A1, Col2a1, Col9a2 and CD-RAP
genes each contain two SOX9 binding sites arranged in
opposite orientation to each other and separated by 3 or
4bp (8–12). Mutation of either site in a pair inactivates
those enhancers, suggesting that dimeric SOX9 binding
is required for transcriptional activation of these genes.
The COL9A1 enhancer, in contrast, contains four SOX9
binding sites arranged in two pairs.
This two-pair arrangement initially suggested
the possibility of two independent enhancer elements.
A shorter element (D1/D2) containing only one of the two
pairs (including the site that had previously been shown to
be important for COL9A1 enhancer activity), however,
was completely inactive in RCS cells. Even when multi-
merized to four tandem copies containing a total of eight
SOX9 binding sites arranged in four pairs, this element
was inactive. In contrast, a single copy of the longer
M1/M2/D1/D2 element containing all four SOX9 binding
sites arranged in two pairs showed enhancer activity in
chondrocytic cells and was activated by SOX9 in 10T1/2
cells. Activity, therefore, is not simply a function of the
number of SOX9 binding sites. Instead, each of the four
sites contributes some essential function.
The importance of each individual SOX9 binding site
to the activity of the COL9A1 enhancer was demonstrated
by generating targeted mutations at each of the four sites.
If activation of the enhancer were accomplished by the
independent contributions of four SOX9 monomers or
by two independently functioning SOX9 dimers, mutation
of any one site would have produced an intermediate level
of transcriptional activation resulting from SOX9 binding
at the three remaining monomeric binding sites or the
one intact dimeric binding site. Instead, the mutation of
any one site completely inactivated the enhancer in
chondrocytic cells, demonstrating that the four SOX9
binding sites function cooperatively and that neither dimer
has the ability to activate transcription independently
in chondrocytic cells.
Mutation of any single SOX9 site completely eliminated
enhancer activity in chondrocytic RCS cells, but the M1,
M2 and D1 mutant enhancers were still partially activated
in 10T1/2 cells by overexpression of SOX9, probably
because the levels of SOX9 were unnaturally high.
When the 66–75 SOX9 dimerization mutant was over-
expressed in 10T1/2 cells, we found that activation of the
four mutant enhancers was the same as with wild-type
SOX9, suggesting that elimination of any individual SOX9
binding site in the enhancer has the same eﬀect as
inactivating the SOX9 dimerization domain. This result
provided additional support for the hypothesis that
dimerization of SOX9at each pair of sites is required for
full transcriptional activation of the M1/M2/D1/D2
enhancer in chondrocytic cells.
To determine whether the two individual SOX9 dimers
interact with one another, 4bp insertions (nearly one-half
turn of the double helix) were generated to change the
spacing from 14 to 18bp between the two pairs of sites.
These insertions inactivated the M1/M2/D1/D2 enhancer,
even though all four of the SOX9 binding site sequences
were unaltered. This result suggested that SOX9 dimers
that are bound at the two pairs of sites must interact
with each other, either directly or through contact with
an additional transcription factor, and that disrupting
their spatial arrangement prevented this interaction from
occurring. Changing the spacing between the two pairs
Figure 8. The D2 site is required for SOX9 binding to the M1/M2/D1/
D2 enhancer in vitro. EMSAs were performed using SOX9 made
in vitro and wild-type or mutant enhancer probes as indicated. Anti-
SOX9 antibody supershifted the wild-type enhancer complex (lane 2).
It also supershifted weaker complexes formed with enhancers bearing
mutations at the M1, M2 and D1 sites, indicating that SOX9 can still
bind these mutated enhancers in vitro (lanes 4, 6 and 8). Mutation of
the D2 site, however, abolished SOX9 binding (lanes 9 and 10).
1184 Nucleic Acids Research, 2007, Vol. 35, No. 4of sites prevented the formation of the functional
transcriptional activating complex.
The in vitro DNA–protein binding data presented here
demonstrates that even though the short D1/D2 element
is transcriptionally inactive, SOX9 is capable of binding
to it as a monomer or dimer in vitro. SOX9 can bind to
the short D1/D2 probe as a monomer at the D2 site, which
is a perfect consensus binding site, even when the D1 site is
mutated. When the D2 site is mutated, in contrast, SOX9
does not bind as a monomer to the intact D1 site.
This suggests that a SOX9 monomer must ﬁrst bind the
D2 site, and then a second SOX9 molecule can bind at the
D1 site and dimerize with the ﬁrst. EMSA results indicate
that SOX9 binding at the M1/M2 pair of sites alone is very
weak, and it is likely that the SOX9 dimer bound at the
M1/M2 pair of sites is stabilized by its interaction
with the D1/D2 SOX9 dimer in the full-length enhancer.
Consistent with this sequential cooperative binding
hypothesis, the D2 site mutation is the only mutation
that prevented all SOX9 binding to the full-length
M1/M2/D1/D2 COL9A1 enhancer probe in EMSA.
It is also the only mutation that made the enhancer
completely nonresponsive to SOX9 overexpression in
10T1/2 cells. We suggest that mutation of the D2 primary
SOX9 binding site prevented the initial SOX9–DNA
interaction, and without this primary interaction, subse-
quent binding of SOX9 to the D1, M2 and M1 sites could
not occur. It follows then that when SOX9 was over-
expressed in 10T1/2 cells, the enhancer activity that was
observed even when the M1, M2 or D1 sites were mutated
was probably produced by monomeric binding of SOX9at
the D2 site. Importantly, however, such activation of the
mutant enhancers occurred only in 10T1/2 cells with
artiﬁcially high levels of SOX9, and never in chondrocytic
cells with physiologically relevant levels of SOX9. In RCS
cells, binding of both SOX9 dimers is essential for
enhancer activity.
The in vitro DNA–protein binding data also emphasizes
another important point: binding of SOX9 to an element
in vitro does not necessarily mean that the element will be
transcriptionally active in vivo. Transcription factors must
not only bind the DNA but also interact with one another,
as well as with any required cofactors in order for
productive transactivation to occur. In the case of the
COL9A1 enhancer, it is possible that cofactors are
required to coordinate the interaction between the two
SOX9 dimers. It is also possible that the two SOX9 dimers
interact directly with one another. Regardless of how
this interaction takes place, the work presented here
demonstrates that the interaction of proteins bound
at four interdependent SOX9 binding sites is essential
for the activity of the COL9A1 enhancer element.
This represents a novel mechanism for transcriptional
activation by SOX9.
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